PFSA Company Profile and Key Details

PFSA has shown mixed momentum, gaining 7.46% over the past week and -68.01% over the past quarter, though year-to-date performance is down -9.26%. Short-term trend indicators are bullishly aligned (SMA20 -64.29%, SMA50 -78.97%, SMA200 -99.39%). The stock’s 14-day RSI is 23.32 (weak momentum), while the ATR of 0.75 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -99.87% below its high and over 8.92% above its low. Average 10-day trading volume of 7.85 million shares is significantly above the 3-month average of 966.82 thousand, indicating heightened recent market interest.

Profusa, Inc. Common Stock has 36.09 million shares outstanding. The public float is 23.09 million shares, elevated short interest at 6.14% of float. This equals 1.63 million shares. The short ratio is 0.27 days. Institutional investors hold 0.56% of the float. Insiders own 1.02%. HRT FINANCIAL LP holds 71.04 thousand shares, STOVER JACK E has 0.00 shares and Knechtel Fred S. has 0.00 shares. Over the past six months, insider transactions show net buying. They sold 49.16 thousand shares across 5 transactions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Profusa, Inc. Common Stock (NASDAQ:PFSA) closed at $27.48 USD, gaining $22.95 (506.62%) from the previous close of $4.53. The stock is currently mid-range between its 52-week high and low $3.22 and $5.19 thousand. With a market capitalization of about $30.30 million, Profusa, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.44). Key stats such as the average daily volume over the past year has been around 1.00 million shares, trading with heavier-than-usual volume. Headquartered in Berkeley, CA, Profusa, Inc. Common Stock operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Jack E. Stover, the company employs approximately 2 people and listed since July 14, 2025. Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors.

Profusa, Inc. Common Stock trades at a P/E ratio of -0.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -1.32 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.31, also above market averages.

Profusa, Inc. Common Stock (NASDAQ:PFSA) shares are flat -9.26% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Profusa, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.12. Our AI forecast model points to short-term weakness (-46.07% over two weeks), a medium-term fall (-13.32% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Profusa, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -46.07%, with price expected at $14.82 by September 01, 2026, within a range of $11.47 to $18.23 3-Month Outlook: Projected fall of -13.32%, reaching $23.82 by November 16, 2026, with a range of $0.00 to $136.69. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by August 18, 2027, within a range of $0.00 to $0.00.